HC Wainwright Lowers Vor Biopharma (NASDAQ:VOR) Price Target to $31.00

Vor Biopharma (NASDAQ:VOR) had its price objective reduced by stock analysts at HC Wainwright from $32.00 to $31.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 107.08% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. TD Cowen initiated coverage on shares of Vor Biopharma in a research note on Wednesday, December 17th. They issued a “buy” rating for the company. Wells Fargo & Company began coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price for the company. Jefferies Financial Group began coverage on shares of Vor Biopharma in a research report on Monday, March 30th. They set a “buy” rating and a $50.00 target price for the company. Wedbush boosted their target price on shares of Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.56.

Vor Biopharma Trading Down 4.0%

VOR stock opened at $14.97 on Wednesday. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80. The company has a fifty day simple moving average of $14.66 and a 200 day simple moving average of $16.67. The firm has a market cap of $731.25 million, a PE ratio of -0.04 and a beta of 1.92.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 589,257 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares of the company’s stock, valued at approximately $75,579,743.19. This represents a 11.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 2,207,379 shares of company stock worth $36,632,973 over the last three months. 0.45% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Ariose Capital Management Ltd acquired a new position in shares of Vor Biopharma during the third quarter worth approximately $5,368,000. Fcpm Iii Services B.V. acquired a new position in shares of Vor Biopharma during the third quarter worth approximately $18,496,000. XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the fourth quarter worth approximately $229,000. Persistent Asset Partners Ltd acquired a new position in shares of Vor Biopharma during the fourth quarter worth approximately $141,000. Finally, Jane Street Group LLC acquired a new position in shares of Vor Biopharma during the first quarter worth approximately $140,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).